CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Insiders were net buyers of CRISPR Therapeutics AG's (NASDAQ:CRSP ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply ...

Avantax Advisory Services Inc. acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

FPA Queens Road Value Fund (“Fund”) returned -2.69% for the fourth quarter of 2024. Click here to read the full commentary.

Harbour Investments Inc. reduced its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.9% during the 4th ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on ...

Among them are CRISPR Therapeutics (NASDAQ: CRSP) and Merck (NYSE: MRK), two companies that develop innovative medical ...

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.